Objective: We evaluated the efficacy of the potent antioxidant C 3 to salvage nigrostriatal neuronal function after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) exposure in nonhuman primates. C 3 is a first-in-class functionalized water-soluble fullerene that reduces oxygen radical species associated with neurodegeneration in in vitro studies. However, C 3 has not been evaluated as a neuroprotective agent in a Parkinson model in vivo. Methods: Macaque fascicularis monkeys were used in a double-blind, placebo-controlled study design. MPTPlesioned primates were given systemic C 3 (n 5 8) or placebo (n 5 7) for 2 months starting 1 week after MPTP. Outcomes included in vivo behavioral measures of motor parkinsonism using a validated nonhuman primate rating scale, kinematic analyses of peak upper extremity velocity, positron emission tomography imaging of 6-[ 11 C]dihydrotetrabenazine (DTBZ; reflects vesicular monoamine transporter type 2), ex vivo quantification of striatal dopamine, and stereologic counts of tyrosine hydroxylase-immunostained neurons in substantia nigra. Results: After 2 months, C 3 -treated monkeys had significantly improved parkinsonian motor ratings, greater striatal FD and DTBZ uptake, and higher striatal dopamine levels. None of the C 3 -treated animals developed any toxicity. Interpretation: Systemic treatment with C 3 reduced striatal injury and improved motor function despite administration after the MPTP injury process had begun. These data strongly support further development of C 3 as a promising therapeutic agent for Parkinson disease. ANN NEUROL 2014;76:393-402 P arkinson disease (PD) is a progressive neurological disorder characterized by tremor, bradykinesia, rigidity, masked facies, gait abnormalities, postural instability, and multiple nonmotor problems. Although the exact etiology of PD remains to be established, animal models and human genetic studies have implicated altered mitochondrial metabolism, chronic activation of inflammatory pathways, oxidation of dopamine to toxic metabolites, and impaired growth factor. 1,2 Current therapies for PD are suboptimal, and there is an unmet need for development of new therapeutic options for this condition. Because mitochondrial and inflammatory processes in PD lead to oxidative injury, a promising approach to new drug design involves compounds with antioxidant qualities. The fullerene compound C 3 (Fig 1) is a promising drug for PD because it has potent antiinflammatory properties in several disease models 3-8 and high aqueous solubility. In this study, we evaluate the in vivo efficacy of parenteral C 3 as a neuroprotectant using
F]fluorodopa (FD; reflects dopa decarboxylase) and [ 11 C]dihydrotetrabenazine (DTBZ; reflects vesicular monoamine transporter type 2), ex vivo quantification of striatal dopamine, and stereologic counts of tyrosine hydroxylase-immunostained neurons in substantia nigra. Results: After 2 months, C 3 -treated monkeys had significantly improved parkinsonian motor ratings, greater striatal FD and DTBZ uptake, and higher striatal dopamine levels. None of the C 3 -treated animals developed any toxicity. Interpretation: Systemic treatment with C 3 reduced striatal injury and improved motor function despite administration after the MPTP injury process had begun. These data strongly support further development of C 3 as a promising therapeutic agent for Parkinson disease. ANN NEUROL 2014; 76:393-402 P arkinson disease (PD) is a progressive neurological disorder characterized by tremor, bradykinesia, rigidity, masked facies, gait abnormalities, postural instability, and multiple nonmotor problems. Although the exact etiology of PD remains to be established, animal models and human genetic studies have implicated altered mitochondrial metabolism, chronic activation of inflammatory pathways, oxidation of dopamine to toxic metabolites, and impaired growth factor. 1,2 Current therapies for PD are suboptimal, and there is an unmet need for development of new therapeutic options for this condition.
Because mitochondrial and inflammatory processes in PD lead to oxidative injury, a promising approach to new drug design involves compounds with antioxidant qualities. The fullerene compound C 3 (Fig 1) is a promising drug for PD because it has potent antiinflammatory properties in several disease models [3] [4] [5] [6] [7] [8] and high aqueous solubility. In this study, we evaluate the in vivo efficacy of parenteral C 3 as a neuroprotectant using a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) primate model of PD. The MPTP-lesioned nonhuman primate provides an excellent platform for testing symptomatic treatments and protective interventions that target processes believed to contribute to the PD pathology. One major difference between the primate-MPTP model and human pathology is the absence of Lewy body formation and the potential mechanism of cell death in human PD, which remains uncertain. However, because of the reliability and consistency of the model, its close similarity to the motor manifestations of PD, and its high predictive value for symptomatic therapies, the primate-MPTP model is quite reasonable for preclinical evaluation of PD drugs. We chose unilateral intracarotid administration of MPTP to produce hemiparkinsonism, thereby permitting the animal to care for itself and allowing the contralateral side of the brain to act as an internal control. 9, 10 A key feature of our study is that we administered the test agent after induction of nigrostriatal injury by MPTP, and thus demonstrate effects that are representative of the postinjury neuroprotective properties of C 3 rather than direct blockade of toxicity of MPTP itself.
Materials and Methods

Experimental Design
A generalized schematic of the experimental design is shown in Figure 2 . The study begins with baseline behavioral (motor parkinsonism rating scales and kinematics) and positron emission tomography (PET) ([ The animal is then treated with internal carotid artery injection of the neurotoxin MPTP, and a 7-day interval ensues during which nigrostriatal injury develops. At the end of the week-long fulmination interval, behavioral measures demonstrate the expected neurotoxicity from MPTP, and the animals are randomized into treatment and control arms that involve parenteral infusion of either C 3 or placebo for a total of 8 weeks. During the treatment phase, behavioral measures (parkinsonism ratings and kinematics) are performed repeatedly to monitor the condition of the animals. At the end of the treatment phase (ie, 9 weeks after MPTP injection, and 8 weeks after starting C 3 or placebo administration), terminal PET measures (DTBZ and FD) are made. The animal is then euthanized, and the brain is removed for in vitro measures of striatal dopamine and stereologic measures of tyrosine hydroxylase (TH)-immunostained neurons in substantia nigra (SN). Note that the infusions begin 7 days after administration of MPTP, so any differences observed between measures of the treatment and control arms can be attributed to the neuroprotective effects of the infusions, rather than to simple blockade of the initial tissue insult from the neurotoxin MPTP.
ETHICS STATEMENT ON USE OF ANIMALS. Experiments were conducted on 15 male Macaca fascicularis monkeys: 7 controls and 8 treated with C 3 (mean ages 5 7.6 6 2.2 and 8.1 6 2.3, respectively; Table) . We used the minimum number of animals necessary for adequate statistical power, and in accordance with the recommendations of the Weatherall report "The Use of Non-Human Primates in Research took all steps to ameliorate suffering in our studies. Guidelines prescribed by the NIH Guide for the Care and Use of Laboratory Animals were followed, and this work was approved by the institutional animal care and use committee at Washington University in St Louis. All animals were housed individually; maintained in facilities with 12-hour dark and light cycles; provided access to FIGURE 1: Chemical structure of C 3 . Molecular structure shows the 3 malonic acid groups of C 3 attached to the fullerene C60 sphere through cyclopropane carbons at the e, e, e positions of C60, giving the molecule C 3 symmetry. The C 3 symmetry gives the compound dipolar character, which enhances distribution across neuronal cell membranes.
FIGURE 2: Schematic of study design, illustrating the major aspects of the study. Baseline measures (behavioral, positron emission tomography [PET] ) precede treatment with intracarotid 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). One week after MPTP administration, each animal is assessed to verify nigrostriatal damage, and randomized to either a treatment (C 3 ) or placebo infusion for 8 weeks. Repeated behavioral measures are made during the 8 weeks of infusion. At the end of the infusion interval, terminal PET measures are done, the animal is euthanized. and in vitro measures (dopamine, tyrosine hydroxylase) are performed. Note that the process for the treatment and control arms is identical, and that both infusions begin well after (7 days) administration of neurotoxin.
food and water ad libitum; and equally engaged with a variety of psychologically enriching tasks, such as watching movies or playing with appropriate toys.
BLINDING OF STUDY. Treatment randomization preceded acquisition of monkeys to avoid potential bias introduced by the size or health of an animal. For each primate, a pair of 2ml mini-osmotic pumps (Alzet, Cupertino, CA; model 2ML4, infusion rate 5 2.5ll/hr) containing either C 3 (200mg/ml; delivering 3 mg/kg/day) or placebo solution (color-matched with Durkee red food coloring in 0.9% sodium chloride injection, USP [United States Pharmacopeial]) was shipped to Washington University from the University of California, San Diego labeled with the animal's identification code but no other information. Behavioral measures, PET measures, and other analyses were carried out by investigators blinded to treatment group (ie, C 3 or placebo). After all data had been collected and compiled at the completion of the study, an investigator not involved in data acquisition or statistical analyses divided the data from the main spreadsheet into 2 spreadsheets based on treatment. This information was then sent to a blinded biostatistician who had not been involved with any of the study previously, and who was unaware of the identity of either treatment. No data were excluded for any animal.
MPTP ADMINISTRATION. Animals were fasted overnight, with free access to water until 2 hours prior to MPTP injection. Anesthesia was induced with ketamine (10mg/kg intramuscularly), followed by endotracheal intubation and maintenance of anesthesia using inhaled isoflurane (3%). MPTP (Sigma, St Louis, MO) in 0.9% sodium chloride injection, USP (0.1mg/ml) at a dose of 0.25mg/kg was infused over 30 minutes not faster than 1ml/min into the right internal carotid artery. 10 Location of the infusion catheter was confirmed with angiograms before and after MPTP infusion. Each animal was allowed to recover with constant observation until it was able to drink and care for itself independently. Full biohazard/neurotoxin precautions for MPTP were taken prior to, during, and after the injection, and all excretions for the next 24 hours were isolated and disposed of appropriately. Proper safety procedures were followed for handling MPTP and all contaminated tissues and waste products. 11 Intracarotid MPTP injection as performed here has been shown to produce stable hemiparkinsonism lasting >1.5 years contralateral to the lesioned side of the brain. >40 days, and this stability is enhanced when maintained as a concentrated solution (as in the Alzet pumps for this study; Dugan et al, unpublished data). After preparation of C 3 and loading of the pumps at the University of California, San Diego, each pair of pumps were placed in a sterile 50ml plastic tube, and shipped overnight on wet ice to Washington University. After receipt, 0.9% sodium chloride injection USP was added to the tube to prime the pumps, which were inserted subcutaneously (first 4 animals) or intraperitoneally (remaining monkeys) the next day, while the animal was anesthetized. Each monkey had 2 pumps inserted at a time, and the total dose of C 3 from both pumps was 3mg/kg/day. This dose was selected based upon preliminary studies of tolerability and efficacy in mice and rats, which showed no long-term toxicity with 2 years of systemic treatment at 1mg/kg/day 6, 12 or 3mg/kg per day, 13 and the half-life of C 3 , which is 8 hours in plasma (mice, monkeys). In mice, the lethal dose for 50% (LD 50 ) for a single bolus of C 3 is 50mg/kg, and for chronic infusion as in the current study it is >30mg/kg/day (Dugan et al, unpublished data); no LD 50 studies were performed in monkeys, but blood tests for hematologic, renal, and hepatic toxicity showed no difference in values between placebo and C 3 -treated animals. The placebo solution was color-matched to assure that the surgical team was blind to the treatment. After the first month of treatment, pumps were replaced for delivery of a second month of drug infusion.
Behavioral Measures
NONHUMAN PRIMATE PARKINSONISM RATING SCA-LE. We rated motor parkinsonism using a validated rating scale developed for nonhuman primates. 10 Each animal was videotaped at the same time of day (early morning) several times before MPTP treatment for baseline behavioral ratings, then several times per week after MPTP until euthanasia. Animals were trained using positive conditioning only to follow a behavioral protocol that consisted of (1) walking back and forth 33 in a straight corridor for 15 feet, (2) walking in a circle 63 in a room (3 clockwise and 3 counterclockwise turns), and (3) Fifteen male Macaque fascicularis monkeys were enrolled. There were no differences in age (p 5 0.69) or weight (p 5 0.95) between treatment groups at baseline (just prior to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injection).
reaching 103 with each hand at full arm's length for a food item held by the trainer. Each behavioral session was video recorded, and the same observer blinded to the treatment group rated each video. 10 Briefly, ratings included a 0 to 3 scale (0 5 unaffected, 1 5 mildly affected, 2 5 moderately affected, and 3 5 severely affected) for parkinsonian features (bradykinesia, tremor, and flexed posturing). This yielded a composite parkinsonism score ranging from 0 to 18 per side. We used for the analysis the parkinsonism score at various times up to 2 months after MPTP just prior to euthanasia. During these studies, animals were always able to care for themselves despite not receiving any antiparkinsonism drugs. One C 3 -treated animal did not have final behavioral ratings included because the video was accidentally destroyed. All other data from this animal, including kinematic data, were included.
KINEMATIC ANALYSIS OF UPPER EXTREMITY MOTOR
VELOCITY. To assess the ability of treatment to maintain normal upper limb motor speed, animals were analyzed using a video-based kinematics assessment as previously described. 14 The primates had baseline ratings before MPTP, ratings after MPTP, and then were repeatedly rated during the 60 days of infusion with either C 3 or placebo. Monkeys were trained to sit in a primate chair and to reach for and eat bits of fruit as behavior reinforcement. Each animal had a training period of 2 to 3 months with five 30-minute sessions per week. Within a few weeks, they became accustomed to the trainer and the transfers from home cage to training chair. Once an animal learned the task, the kinematics of the movement were measured using reflective markers placed on the lateral aspect of the index finger, wrist, elbow, and shoulder to aid in visualization and timing. Animals were videotaped in the sagittal plane during a minimum of 12 reaches to an apple slice target. The kinematic data were recorded at 60 frames per second using a motion analysis system from Peak Performance Technologies (Centennial, CO; Motus 2000). A time code was generated and recorded with the video information. The video images were digitized, and the joint markers were tracked to permit measurement of the movement. The reaching task was performed and videotaped in baseline sessions every other day for 5 sessions total, and continued every other day beginning the day after MPTP injection for the next 4 weeks, then twice a week for the following 9 weeks until euthanasia. The kinematic data were analyzed off-line with the Motus 2000 motion analysis system and custom-written software to obtain velocity and acceleration information from the reaching task. The movement trajectories of the entire limb and of individual joints were quantified and analyzed with respect to joint angle relationships and variability from trial to trial in both the maintained posture and reaching phases of the task. All analyses were performed by investigators blind to treatment group.
PET Measures
In addition to the behavioral measures, we also carried out PET imaging to assess striatal dopa decarboxylase using FD and vesicular monoamine transporter type 2 (VMAT2) using DTBZ. Both PET measures were done before MPTP injection to acquire baseline data. Repeat PET measures using both tracers were also done at the end of the 2-month infusion with either C 3 or placebo solution. To mimic the clinical situation in which PD patients have pre-existing dopaminergic neuronal injury, administration of C 3 or placebo was initiated 7 days after MPTP. Note that unlike systemic administration of MPTP, which causes bilateral loss of dopamine neurons, the unilateral intracarotid MPTP infusion model used in these studies spares the contralateral side. 10 This situation allowed the noninjured side to serve as an internal control for each individual animal.
PET TRACERS. Carbon-11 and fluorine-18 for radiotracer syntheses were produced using the Washington University RDS-Eclipse cyclotron, and labeling substrates were from ABX Advanced Biochemical Compounds (Radeberg, Germany 15 using the Siemens Microsystems (Knoxville, TN) MicroPET Focus 220 scanner. A transmission scan was collected for individual attenuation measurements at each imaging session. Afterward, up to 10mCi (10nmol) of DTBZ was infused intravenously (i.v.) over 60 seconds, followed by PET scans with three 1-minute frames, four 2-minute frames, three 3-minute frames, and then eight 5-minute frames for the next 40 minutes (1 hour total). Three hours later, 3 to 10mCi (33-100mmol) of FD was infused i.v. over 60 seconds, and PET scans were collected for 120 minutes (three 1-minute frames, four 2-minute frames, three 3-minute frames, and twenty 5-minute frames). 15 MAGNETIC RESONANCE IMAGING. Magnetic resonance images permit identification of relevant volumes of interest (VOIs) from the PET images. A Siemens Magnetom Sonata 1.5T system was used for these studies. At each imaging session, gradient and shim coil currents were adjusted to correct for spatial inhomogeneities using the scanner's multiaxis-projection shim program. We collected a 3-dimensional magnetization prepared rapid gradient echo (MP-RAGE) sequence (repetition time 5 2,400 milliseconds, echo time 5 3.93 milliseconds, inversion time 5 1,100 milliseconds, flip angle 5 7,256 3 256 3 192 matrix, 2 averages, acquisition time 5 15:23) to produce high-resolution T1 images (0.8mm isotropic voxels).
PET IMAGE ANALYSIS. All image analysis was done by investigators blinded to the treatment status of the monkeys. PET image reconstruction considered randoms, scatter, attenuation, and dead time. Reconstructed resolution was <2.0mm fullwidth half-maximum for all 3 dimensions at the center of the field of view. Correction for movement of individual frames was unnecessary, because the anesthetized animal's head was immobile. The first baseline PET image for each animal acted as the target image, with subsequent PET images collected on subsequent days coregistered to it. Caudate, putamen, and an occipital region (as a reference) were manually traced on the MP-RAGE for each animal. The MP-RAGE was coregistered to the target PET scan of the corresponding animal using a vector gradient method, and the traced VOIs were transformed into PET space using the same transformation matrix. 16, 17 To reduce volume averaging with the neighboring regions, the magnetic resonance imaging-based striatal VOIs were trimmed to include only voxels with at least 90% of the maximal counts within that VOI. The reference region included a pair of hemicylinders in occipital cortex on either side of the midline, set back from the midline and the posterior edges to avoid vascular activity and transformed to PET space as described above. After extracting the tissue activity curves, we calculated the influx constant K OCC for FD (data from 24-94 minutes), 18 and the nondisplaceable binding potential (BP ND ) for DTBZ (15-60 minutes), 19 as previously described. 15 
In Vitro Measures
EUTHANASIA AND SAMPLE PREPARATION. Animals were euthanized with i.v. pentobarbital (120mg/kg; Somnasol Euthanasia; Butler Schein Animal Health, Dublin, OH) 2 months after initiation of osmotic pump infusions, which corresponds to 9 weeks after MPTP injection. Brain tissue was handled as described previously. 10 The brain was removed within 10 minutes, and the hemispheres and midbrain were separated. The hemispheres were sliced in the coronal plane. Standard punch biopsies were collected from caudate and putamen bilaterally, frozen quickly on dry ice snow, and stored in a 280 C freezer until dopamine assay. The midbrain was fixed in 4% paraformaldehyde in 0.1M phosphate-buffered saline solution.
ANALYSIS OF STRIATAL DOPAMINE LEVELS. Striatal dopamine was measured in the tissue extracts using highperformance liquid chromatography with electrochemical detection. 11, 20 The analytical data were expressed as nanograms per gram of brain tissue. The concentration of dopamine in the lesioned caudate, putamen, and striatum was divided by the concentration in the nonlesioned side to normalize for differences across animals.
CELL COUNTS OF DOPAMINERGIC TH IMMUNOSTAINING
NIGRAL NEURONS. The brains were sliced and immunostained with TH using 3,3 0 -diaminobenzidine solution amplification. Unbiased stereological counts of nigrostriatal neurons were done on immunostained midbrain slices, focusing on the SN pars compacta (SNpc) as previously described. 10 
Statistics Analysis
All data from the above studies were analyzed by repeated measures analysis of variance (ANOVA) followed by Tukey post hoc test by SigmaStat statistical software (Systat Software, San Jose, CA), with significance set at p < 0.05. For in vivo PET measures as well as in vitro quantification of striatal dopamine concentration and TH-positive cell counts, the ratio of the lesioned side to unlesioned side for each animal was used for statistical analysis to control for interindividual differences. Statistical analyses with the parkinsonian rating scales were done with the nonparametric Mann-Whitney U (rank sum) test. Data for the various study results are presented as the mean-6 standard error of the mean (SEM) for all the data in each group. In the statistical analysis, no data were excluded from any subject or any test.
Results
Behavioral Measures
PARKINSONISM RATINGS. Monkeys were rated throughout the study. Figure 3 shows the mean parkinsonism motor ratings for the C 3 -treated and control animals as a function of time. Note that early after MPTP administration, the scores for the 2 arms of the study are not significantly different. However, as infusion times increase, the 2 curves first statistically differ (MannWhitney-Wilcoxon, p 5 0.026) beginning 40 days after the start of the C 3 infusion, with declining parkinsonism ratings in the treated animals but no drop in these ratings in the control animals. The final ratings at the end of the 2-month treatment period are shown in Figure 4 . Data are the mean 6 SEM for all animals in the treatment (n 5 7) and control (n 5 7) groups. C 3 -treated animals had significantly lower parkinsonian scores than placebo-treated animals, indicating less bradykinesia, flexed posturing, and tremor when the animals received C 3 infusion (p 5 0.007, Mann-Whitney-Wilcoxon rank sum test).
KINEMATIC SCORES OF UPPER EXTREMITY PEAK
VELOCITY. The upper extremity peak velocity was compared to the baseline velocity of the same limb following the same stimulus prior to MPTP lesioning. Results are presented as the mean percentage decrease in velocity from baseline, with a smaller decrease indicating preservation of function (less bradykinesia; Fig 5) . Preservation of peak upper extremity reaching in the C 3 -treated monkeys was not significantly different from control animals, but showed a strong trend (p 5 0.078 by ANOVA).
PET Measures
PET IMAGING: FD AND DTBZ. Figure 6A illustrates FD and DTBZ striatal uptake at baseline and 2 months after MPTP in 2 control monkeys, and Figure 6B shows the similar PET images for 2 C 3 -treated monkeys. Figure 7 presents the quantified PET measures taken from all animals in the C 3 -treated and placebo-infused arm before and after 2 months of infusion. Data are the means 6 SEM for all animals (C 3 , n 5 8; placebo, n 5 7). Compared to placebo, infusion of C 3 provides substantial preservation of striatal DTBZ BP ND (see Fig 7A) and striatal FD K occ (see Fig 7B) compared to controls.
In Vitro Measures
STRIATAL DOPAMINE LEVELS. The dopamine concentrations per milligram of tissue for caudate, putamen, and striatum are shown in Figure 8 . Consistent with the PET measures, dopamine levels in all striatal tissues of the lesioned striata were significantly higher in the C 3 -treated animals compared to the controls (p < 0.001; 2-way ANOVA, Tukey post hoc test).
TH-IMMUNOREACTIVE NEURONS IN THE
SNpc. Qualitatively, we observed substantial loss of TH immunoreactivity in processes in the nigra, which was in many cases more dramatic than the loss of TH-positive cell bodies (Fig 9A-C) . Images of TH-stained slices containing the SN from 2 separate pairs of animals are shown in Figure 9B and C (and see insets), with the insets comparing fiber staining in the nonlesioned and lesioned sides. The SNpc on the lesioned side had a >50% decrease in the number of TH-immunoreactive neurons compared to the unlesioned side in all animals (see Fig 9D) . A trend toward preservation of TH-positive cells in C 3 -treated animals did not reach significance, but the degree of nigral cell loss (about 50%) was close to that which is associated with nearly complete loss of striatal dopamine. 10 Quantitative fiber density measurements were not performed, because TH staining intensity was calibrated to allow reliable cell counts, not fiber counts.
Discussion
Treatment with C 3 reduced striatal injury and improved functional outcomes in a primate model of PD, even after the injury process had begun. These data strongly support further development of C 3 as a therapeutic agent for PD. C 3 is a functionalized fullerene bearing 3 malonic acid groups (see Fig 1) that impart aqueous solubility to the C 60 core, as well as amphiphilic (dipolar) character that improves intercalation into neuronal membranes to enhance neuroprotective effects. C 3 harnesses the unique electronic properties of the C 60 fullerene core to catalytically eliminate superoxide anion and other reactive oxygen species believed to play a role in excitotoxic neuronal death. C 3 also exhibits anti-inflammatory properties, 4, 7, 8 and reduces oxidative injury in several disease models, 3, 5, 7 including MPTP and 6-hydroxydopamineinduced neuronal cell death. 5 The compound localizes in mitochondria, 6, 21 and functionally replaces lost mitochondrial superoxide dismutase (Sod2) 6 in Sod2 2/2 mice.
Unlike other antioxidants, C 3 does not require active recycling to maintain activity, and does not become a pro-oxidant. Rather, the fullerene demonstrates activity that is similar to that of the native superoxide dismutase enzyme, allowing C 3 to eliminate the reactive oxygen species, superoxide, by catalytic dismutation. There are several special characteristics of C 3 relevant for neuroprotection in PD that also may help attenuate MPTP injury. First, C 3 scavenges injurious free radicals regardless of whether of excitotoxic or neuroinflammatory origin. Rather than targeting a specific step of a neurochemical pathway, the scavenging mechanism of C 3 can provide comprehensive benefit by neutralizing radicals generated from multiple simultaneous biochemical pathways. Second, C 3 has a fullerene core that acts as a highcapacity free-radical catalyst, resulting in a high stoichiometric ratio of radical to fullerene. Third, aqueous solubility designed onto the lipophilic core provides an important pharmaceutical advantage that enhances penetration of the blood-brain barrier (BBB) after parenteral administration. Taken together, these characteristics make C 3 a highly favorable neuroprotective drug for testing in human PD.
We hypothesized that systemically administered C 3 1 week after MPTP would attenuate nigrostriatal injury and behavioral deficits. To evaluate this hypothesis, we carried out a randomized, double-blind, placebo-controlled longitudinal study in MPTP-lesioned M. fascicularis monkeys and emphasized blinding of all investigators to treatment throughout the study and data analysis. Furthermore, we waited 7 days after MPTP administration to start treatment with C 3 or placebo. Thus, differences between the C 3 and placebo groups can be attributed to neuroprotective effects of C 3 and not to interference with the initial steps of MPTP-induced neurotoxicity. This experimental design provides additional confidence in the efficacy of C 3 and likely success in humans with PD who have already begun the degenerative process.
The behavioral measures suggest a neuroprotective benefit of C 3 . Parkinsonian ratings were performed periodically throughout the study using a validated rating scale (see Fig 2) . Both C 3 -treatment and placebo arms started with similar degrees of parkinsonism after MPTP (see Fig 3) . However, animals treated with C 3 began to improve 3 to 4 weeks after MPTP (a statistically significant difference between the 2 groups of animals was first reached at 30 days after the start of C 3 ) and approached baseline measures by the end of the study, whereas the animals in the placebo arm did not improve. The slow onset of behavioral effects of C 3 may reflect the pharmacokinetics of the drug. Although steady state in the plasma compartment may have been reached before 30 days, partitioning of C 3 across the BBB and distribution to target sites within the central nervous system (CNS) is likely slower. After 2 months of treatment, the C 3 -treated animals had significantly less parkinsonism, but the faster quantified reaching velocity did not reach statistical significance. The parkinsonism rating scale integrates more motor behaviors than the reaching task and may be a more comprehensive measure of motor performance.
The PET measures of nigrostriatal terminal fields reflect 2 different components of presynaptic dopaminergic nigrostriatal neurons. FD reflects primarily decarboxylase activity and storage, whereas DTBZ reflects the status of VMAT2-specific binding sites on presynaptic vesicles that store dopamine. As revealed in Figures 6  and 7 , the striatal uptake of both of these radiotracers is significantly preserved in the C 3 -treated animals. Together with the behavioral measures, these PET measures of CNS changes are convincing evidence for a central mechanism involving nigrostriatal neurons whereby C 3 provides its pharmacological effect.
The in vitro measures from brain tissue (see Fig 2) provide biochemical validation for the behavioral and in vivo PET measures. The in vitro measures of dopamine concentration within caudate and putamen show a significant increase for the C 3 -treatment group (see Fig 8) .
In contrast, stereologic counts of nigral cell bodies were not statistically different between the C 3 and control groups. In all animals, the lesioned SNpc had close to 50% decrease in nigral cell counts compared to the nonlesioned side. This FIGURE 8: Striatal dopamine levels. Tissue dopamine concentration per milligram wet weight of tissue was determined by high-performance liquid chromatography at the completion of the study, following the 2-month drug treatment. The concentration of dopamine in the lesioned caudate (Caud), putamen (Putam), and striatum (Striat) was divided by the concentration in the nonlesioned side to control for differences in brain size or time to dissect the tissue. There was significant (p < 0.001) preservation of dopamine in all 3 regions in C 3 -treated animals compared to placebotreated controls (2-way analysis of variance, Tukey post hoc test).
may have implications for the site of recovery or protection provided by C 3 . C 3 could either preferentially have its effects in terminal fields, or alternatively it could have a more general action on nigrostriatal neurons, with terminal field recovery just exceeding the flooring threshold that provides clinical benefit. Preferential action of C 3 at terminal fields would be reasonable if this molecule is taken up at terminal fields, where one might anticipate a higher concentration than at distant cell bodies. One might speculate that either longer time of treatment or possibly a higher dose could enhance recovery at the cell body level. Further investigations are needed to clarify these issues. We also observed qualitatively substantial greater loss of TH-immunoreactive fibers in SNpc in placebo-treated animals, which was more dramatic than the loss of TH-positive cell bodies (see Fig 9) . We could not perform quantitative fiber density measurements, because TH staining intensity was calibrated to allow reliable cell body counts, and not optimized for fiber counts. Nevertheless, these findings provide a suggestion about the potential mechanisms of action, and targets, of C 3 .
Our results demonstrate that systemically administered C 3 modified severity in the nonhuman primate MPTP model of PD. Two caveats require consideration. The current study was relatively short, with only 2 months of treatment. Whether treatment effects would persist or potentially improve with longer therapy remains unknown. Clearly, the MPTP model provides an excellent system to screen pharmacologic interventions to ameliorate parkinsonian motor manifestations and some nonmotor manifestations, 22 but it is a more tenuous model for testing treatments aimed at the etiopathology of PD in humans. Nevertheless, testing interventions using the MPTP-induced injury model in nonhuman primates provides important clues for potential candidates for therapeutic trials in PD. 23 However, only a properly controlled trial in human subjects with PD can determine the clinical efficacy of C 3 . Fortunately, in these preclinical studies we found little evidence of toxicity for C 3 . Therefore, the therapeutic doses used in this study suggest that this therapy should be well tolerated in humans.
